Please use this identifier to cite or link to this item: https://doi.org/10.3390/cancers8070068
DC FieldValue
dc.titlePtk7 and Mcc, unfancied components in non-canonical Wnt signaling and cancer
dc.contributor.authorDunn, N.R
dc.contributor.authorTolwinski, N.S
dc.date.accessioned2020-10-22T02:55:19Z
dc.date.available2020-10-22T02:55:19Z
dc.date.issued2016
dc.identifier.citationDunn, N.R, Tolwinski, N.S (2016). Ptk7 and Mcc, unfancied components in non-canonical Wnt signaling and cancer. Cancers 8 (7) : 68. ScholarBank@NUS Repository. https://doi.org/10.3390/cancers8070068
dc.identifier.issn20726694
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/178895
dc.description.abstractHuman development uses a remarkably small number of signal transduction pathways to organize vastly complicated tissues. These pathways are commonly associated with disease in adults if activated inappropriately. One such signaling pathway, Wnt, solves the too few pathways conundrum by having many alternate pathways within the Wnt network. The main or “canonical” Wnt pathway has been studied in great detail, and among its numerous downstream components, several have been identified as drug targets that have led to cancer treatments currently in clinical trials. In contrast, the non-canonical Wnt pathways are less well characterized, and few if any possible drug targets exist to tackle cancers caused by dysregulation of these Wnt offshoots. In this review, we focus on two molecules—Protein Tyrosine Kinase 7 (Ptk7) and Mutated in Colorectal Cancer (Mcc)—that do not fit perfectly into the non-canonical pathways described to date and whose roles in cancer are ill defined. We will summarize work from our laboratories as well as many others revealing unexpected links between these two proteins and Wnt signaling both in cancer progression and during vertebrate and invertebrate embryonic development. We propose that future studies focused on delineating the signaling machinery downstream of Ptk7 and Mcc will provide new, hitherto unanticipated drug targets to combat cancer metastasis. © 2016 by the authors; licensee MDPI, Basel, Switzerland.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.subjectdishevelled protein
dc.subjectmutated in colorectal cancer protein
dc.subjectoncoprotein
dc.subjectprotein tyrosine kinase
dc.subjectprotein tyrosine kinase 7
dc.subjectunclassified drug
dc.subjectbinding affinity
dc.subjectcancer growth
dc.subjectcell proliferation
dc.subjectcolorectal cancer
dc.subjectcytoskeleton
dc.subjectembryo development
dc.subjectgastrulation
dc.subjecthuman
dc.subjectmorphogenesis
dc.subjectphenotype
dc.subjectprotein analysis
dc.subjectprotein binding
dc.subjectprotein degradation
dc.subjectprotein domain
dc.subjectprotein function
dc.subjectprotein phosphorylation
dc.subjectprotein protein interaction
dc.subjectReview
dc.subjectubiquitination
dc.subjectWnt signaling pathway
dc.typeReview
dc.contributor.departmentYALE-NUS COLLEGE
dc.description.doi10.3390/cancers8070068
dc.description.sourcetitleCancers
dc.description.volume8
dc.description.issue7
dc.description.page68
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3390_cancers8070068.pdf1.42 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons